PAVmed Inc. Series Z Warrant
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing… Read more
PAVmed Inc. Series Z Warrant (PAVMZ) - Total Liabilities
Latest total liabilities as of March 2025: $11.89 Billion USD
Based on the latest financial reports, PAVmed Inc. Series Z Warrant (PAVMZ) has total liabilities worth $11.89 Billion USD as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PAVmed Inc. Series Z Warrant - Total Liabilities Trend (2014–2024)
This chart illustrates how PAVmed Inc. Series Z Warrant's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
PAVmed Inc. Series Z Warrant Competitors by Total Liabilities
The table below lists competitors of PAVmed Inc. Series Z Warrant ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CHOW TAI FOOK JEWEL
BE:1CT
|
Germany | €60.04 Billion |
|
Tiger Reef Inc
PINK:TGRR
|
USA | $1.14 Million |
|
Lowell Resources Fund
AU:LRT
|
Australia | AU$2.41 Million |
|
Record PLC
LSE:REC
|
UK | GBX13.32 Million |
|
Acura Pharmaceuticals Inc
OTCQB:ACUR
|
USA | $1.27 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down PAVmed Inc. Series Z Warrant's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PAVmed Inc. Series Z Warrant's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PAVmed Inc. Series Z Warrant (2014–2024)
The table below shows the annual total liabilities of PAVmed Inc. Series Z Warrant from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $37.69 Million | -34.03% |
| 2023-12-31 | $57.14 Million | +32.73% |
| 2022-12-31 | $43.05 Million | +469.54% |
| 2021-12-31 | $7.56 Million | -62.68% |
| 2020-12-31 | $20.25 Million | +70.48% |
| 2019-12-31 | $11.88 Million | +8.26% |
| 2018-12-31 | $10.97 Million | +144.49% |
| 2017-12-31 | $4.49 Million | +277.31% |
| 2016-12-31 | $1.19 Million | +105.02% |
| 2015-12-31 | $580.17K | +1127.90% |
| 2014-12-31 | $47.25K | -- |